Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lemborexant as a Potential Pharmacotherapy for the Treatment of Cannabis Use Disorder (CUD)

NCT07802990 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT07802990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07802990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lemborexant as a Potential Pharmacotherapy for the Treatment of Cannabis Use Disorder (CUD)
Lead sponsor
University of Calgary
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2028
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis use disorder